<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73875">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01900743</url>
  </required_header>
  <id_info>
    <org_study_id>REGO-SARC-1214</org_study_id>
    <nct_id>NCT01900743</nct_id>
  </id_info>
  <brief_title>Phase II Study of Regorafenib in Metastatic Soft Tissue Sarcoma</brief_title>
  <acronym>REGO-SARC</acronym>
  <official_title>Activity and Safety of Regorafenib in Patients With Metastatic Soft Tissue Sarcoma Previously Treated With Anthracycline-based Chemotherapy : a Multinational, Randomized, Phase II, Placebo-controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Oscar Lambret</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Oscar Lambret</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an international (France, Austria and Germany), randomized, double-blind,
      placebo-controlled, phase II study to evaluate the efficacy and safety of regorafenib in
      patients with histologically proven metastatic and/or unresectable Soft Tissue Sarcoma (STS)
      after failure or intolerance to doxorubicin (or other anthracycline).

      Four strata will be defined:

      Strata A: Liposarcoma Strata B: Leiomyosarcoma Strata C: Synovial sarcoma Strata D: other
      sarcomas (see Appendix C) Approximately 192 patients who meet the eligibility criteria will
      be randomly assigned in a 1:1 ratio to one of the treatment groups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The standard of care for metastatic soft tissue sarcoma is doxorubicin +/- ifosfamide. After
      failure or intolerance to doxorubicin, there is no standard of care. In Europe, two are
      currently approved for the treatment of soft tissue sarcoma after failure/intolerance to
      doxorubicin: trabectedin (Yondelis®) for all histological subtype and pazopanib (Votrient ®)
      for all subtypes excluding liposarcomas. Nevertheless, none of these drugs improve the
      overall survival over placebo.

      The study is composed of 3 periods:

        1. A Screening Period,

        2. A Treatment Period,

        3. And a Survival Follow-up Period. Patients randomized to be treated with regorafenib
           will receive the treatment orally for 3 weeks of every 4 week (28 days) cycle (ie, 3
           weeks on/1 week off).

      Patients randomized to the placebo arm will be treated for 3 weeks of every 4 weeks cycle
      (ie, 3 weeks on/1 week off).

      In addition to the regorafenib and placebo treatments, patients will receive best supportive
      care. Best supportive care includes any method to preserve the comfort and dignity of the
      patients and excludes any disease-specific anti-neoplastic therapy such as any kinase
      inhibitor,chemotherapy, radiation therapy, or surgical intervention.

      Patients receiving placebo, who experience disease progression may be offered open-label
      regorafenib(cross-over option).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">April 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Growth modulation index in patients receiving regorafenib after randomization</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity according to NCI-CTC AE V4.0.</measure>
    <time_frame>Baseline, every 4 weeks, up to the end of study</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free rate at 3 and 6 months (PFR-3 and PFR-6)</measure>
    <time_frame>At month 3 and at month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>According to the RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>According to the RECIST 1.1 Every 4 weeks, Up to 2 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Time from the date of randomization to the date of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Potential predictive factors for regorafenib response.</measure>
    <time_frame>Up to 2 years</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">192</enrollment>
  <condition>Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Regorafenib (160 mg/d) once daily for 3 weeks on / 1 week off plus Best Supportive Care (BSC) until progression (according to RECIST 1.1), intolerance or consent withdrawal.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regorafenib</intervention_name>
    <description>Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.</description>
    <arm_group_label>Arm A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression</description>
    <arm_group_label>Arm B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥18 years

          -  Histological documentation of soft tissue sarcoma (including uterus)with available
             Formalin Fixed Paraffin Embedded (FFPE) blocks

          -  Prior treatment with doxorubicin or other anthracycline

          -  Metastatic disease not amenable to surgical resection with curative intent

          -  Documentation of progression within the last 6 months

          -  Measurable disease, defined as at least 1 unidimensionally measurable lesion on a CT
             scan as defined by RECIST 1.1.

          -  Performance status ≤1(ECOG)

          -  Life expectancy ≤ 3 months

          -  Adequate bone marrow, renal, and hepatic function:

          -  INR/PTT ≤1.5 x ULN Patients who are therapeutically treated with an agent such as
             warfarin or heparin will be allowed to participate provided that no prior evidence of
             underlying abnormality in coagulation parameters exists. Close monitoring will be
             performed until INR/PTT is stable.

          -  Women of childbearing potential and male patients must agree to use adequate
             contraception for the duration of study participation and up to 3 months following
             completion of therapy.

          -  Recovery to NCI-CTCAE v4.0 Grade 0 or 1 level or recovery to baseline preceding the
             prior treatment from any previous drug/procedure related toxicity (except alopecia,
             anemia, and hypothyroidism).

          -  In the assessment of the investigator, patient is able to comply with study
             requirements

          -  Signed, IRB-approved written informed consent

        Exclusion Criteria:

          -  More than 3 lines of systemic treatment for metastatic sarcoma

          -  Histological subtypes listed in Appendix C (especially GIST, osseous sarcoma,
             embryonal or alveolar rhabdomyosarcoma)

          -  Primary bone sarcoma

          -  Prior treatment with regorafenib

          -  Known history of or concomitant malignancy likely to affect life expectancy in the
             judgment of the investigator

          -  Pregnant or breastfeeding patients. Women of childbearing potential must have a
             pregnancy test performed before start of treatment

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             before start of treatment

          -  Active cardiac disease including any of the following: Congestive heart failure
             (NYHA) ≥Class 2, Unstable angina (angina symptoms at rest), new-onset angina (begun
             within the last 3 months), Cardiac arrhythmias requiring anti-arrhythmic therapy
             (beta blockers or digoxin are permitted)

          -  Uncontrolled hypertension (SBP &gt;150 mmHg or diastolic pressure &gt;90 mmHg despite
             optimal medical management)

          -  Arterial or venous thrombotic or embolic events such as cerebrovascular accident
             (including transient ischemic attacks), deep vein thrombosis, or pulmonary embolism
             (within the last 6 months)

          -  Ongoing infection &gt;Grade 2 according to NCI-CTCAE v4.0

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Known history of chronic hepatitis B or C

          -  Patients with seizure disorder requiring medication

          -  History of organ allograft

          -  Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event &gt; Grade 4
             within 4 weeks of start of treatment

          -  Non-healing wound, ulcer, or bone fracture

          -  Renal failure requiring hemo- or peritoneal dialysis

          -  Dehydration according to NCI-CTC v 4.0 Grade &gt;1

          -  Substance abuse, medical, psychological, or social conditions that may interfere with
             the patient's participation in the study or evaluation of the study results

          -  Known hypersensitivity to any of the study drugs, study drug classes, or excipients
             in the formulation, including lactose

          -  Interstitial lung disease with ongoing signs and symptoms at the time of informed
             consent

          -  Inability to swallow, malabsorption condition

          -  Pleural effusion or ascites that causes respiratory compromise (Grade 2 dyspnea)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>PENEL Nicolas, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Oscar Lambret - France</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Thomas BRODOWICZ, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AKH-Wien - Austria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Viktor GRÜNWALD, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hannover Medical School</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicolas PENEL, MD, PhD</last_name>
    <phone>+33(0)3 20 29 59 20</phone>
    <email>n-penel@o-lambret.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yvette VENDEL, Project Manager</last_name>
    <phone>33 (0)3 20 29 59 18</phone>
    <email>y-vendel@o-lambret.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medizinische Universität Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ferdinand PLONER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin I</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Wolfgang EISTERER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Krankenhaus der Barmherzigen Schwestern Linz</name>
      <address>
        <city>Linz</city>
        <zip>4010</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AKH-Wien</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth LINDER, Director SPA</last_name>
      <phone>(43)1 409 77 25 19</phone>
      <email>Elisabeth.Lindner@cecog.at</email>
    </contact>
    <contact_backup>
      <last_name>Marika ROSNER, CRA Monitor</last_name>
      <phone>(43)1 409 77 25 19</phone>
      <email>marika.rosner@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>Thomas BRODOWICZ, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital St Jacques</name>
      <address>
        <city>Besancon</city>
        <zip>25000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ludivine ROY, CRA</last_name>
      <phone>33 (0)3 81 66 92 31</phone>
      <email>oncologie-recherche-2@chu-besancon.fr</email>
    </contact>
    <investigator>
      <last_name>Loic CHAIGNEAU, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Elsa KABACHER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry NGUYEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine DUPOUY, CRA</last_name>
      <phone>33 (0)5 56 33 32 53</phone>
      <email>m.dupouy@bordeaux-unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Simone MATHOULIN, MD</last_name>
      <phone>33 (0)5 56 33 33 33</phone>
      <email>s.mathoulin@bordeaux-unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Antoine ITALIANO, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Guilhem ROUBAUD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Binh BUI NGUYEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bénédicte GRIFFON, Responsable URC</last_name>
      <phone>33 (0)2 31 45 50 05</phone>
      <email>b.griffon@baclesse.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sophie DANET, CRA</last_name>
      <phone>33 (0)2 31 45 50 02</phone>
      <email>s.danet@baclesse.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Corinne DELCAMBRE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sabine NOAL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre GF Leclercq</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandrine TIAGO, Responsable URC</last_name>
      <phone>33 (0)3 45 34 80 51</phone>
      <email>stiago@cgfl.fr</email>
    </contact>
    <contact_backup>
      <last_name>Erwan PETIT, CRA</last_name>
      <phone>33 (0)3 80 73 77 52</phone>
      <email>epetit@cgfl.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolas ISAMBERT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle DESMOUILINS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Oscar Lambret</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stéphanie CLISANT, Responsable URC</last_name>
      <phone>33 (0)3 20 29 59 35</phone>
      <email>s-clisant@o-lambret.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sandy COURAPIED, CRA</last_name>
      <phone>33 (0)3 20 29 59 35</phone>
      <email>s-courapied@o-lambret.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Nicolas PENEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Eric AMELA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédérik LAESTAIUS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antoine ADENIS, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christelle FLORENT, Responsable URC</last_name>
      <phone>33 (0)4 78 78 27 72</phone>
      <email>christelle.florent@lyon-unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-Yves BLAY, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabelle-Laure RAY-COQUART, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe CASSIER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre BIRON, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre-Etienne HEUDEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital de La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meriem BOUALEM, Responsable URC</last_name>
      <phone>33 (0)4 91 38 46 05</phone>
      <email>meriem.boualem@ap-hm.fr</email>
    </contact>
    <contact_backup>
      <last_name>Josiane ONEZIME, CRA</last_name>
      <phone>33 (0)4 91 38 46 05</phone>
      <email>josiane.onezime@ap-hm.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Florence DUFFAUD, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sébastien SALAS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thanh HUYNH, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmettes</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dominique GENRE, MD</last_name>
      <phone>33 (0)4 91 22 36 67</phone>
      <email>bec@ipc-unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>François BERTUCCI, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Val d'Aurelle</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine GESTIN-BOYER, Responsable</last_name>
      <phone>33 4 67612515</phone>
      <email>christine.gestin-boyer@icm-unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Béatrice SAULQUIN, Responsable URC</last_name>
      <phone>33 (0)2 40 67 99 00</phone>
      <email>beatrice.saulquin@ico-unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuelle BOMPAS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Frédéric ROLLAND, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien VANSTEENE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <zip>06189</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence CULINE, Directrice Déléguée CIRCO</last_name>
      <phone>33 (0)1 42 38 51 10</phone>
      <email>laurence.culine@sls.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Christine LEMAIGNAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Damien POUSSEL, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patricia TRESCA, MD</last_name>
      <phone>33(0)1 56 24 56 32</phone>
      <email>patricia.tresca@curie.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anne BLONDEL, CRA</last_name>
      <phone>33(0)1 44 32 46 86</phone>
      <email>ANNE.BLONDEL@curie.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Sophie PIPERNO-NEUMANN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Valérie LAURENCE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurent MIGNOT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oussema ZEKRI, CRA Manager</last_name>
      <phone>33 (0)2 99 25 31 32</phone>
      <email>o.zekri@rennes-unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre KERBRAT, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe PERRIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien EDELINE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie TALARMIN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Louis-Ferdinand PEPIN, MD</last_name>
      <phone>33 (0)2 32 08 24 54</phone>
      <email>louis.ferdinant.pepin@chb.unicancer.fr</email>
    </contact>
    <contact_backup>
      <last_name>Sabine LORIVEL, CRA</last_name>
      <phone>33 (0)2 32 08 29 28</phone>
      <email>sabine.lorivel@chb-unicancer.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Cécile GUILLEMET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean Christophe THERY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Curie - Hôpital René Huguenin</name>
      <address>
        <city>Saint Cloud</city>
        <zip>92210</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stéphanie DUPONT-CASQUIN, Responsable UIRC</last_name>
      <phone>33 1 47111853</phone>
      <email>stephanie.dupont-casquin@curie.net</email>
    </contact>
    <investigator>
      <last_name>Laurence BOZEC, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Cancérologie Lucien Neuwirth (ICL)</name>
      <address>
        <city>St Priest En Jarez</city>
        <zip>42270</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mathieu ORIOL, CRA</last_name>
      <phone>33 477917071</phone>
      <email>mathieu.oriol@icloire.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier COLLARD, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Claudius Regaud</name>
      <address>
        <city>Toulouse</city>
        <zip>32052</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muriel POUBLANC, Responsable URC</last_name>
      <phone>33 (0)5 61 42 46 74</phone>
      <email>poublanc.muriel@claudiusregaud.fr</email>
    </contact>
    <investigator>
      <last_name>Christine CHEVREAU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carlos GOMEZ-ROCA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Alexis Vautrin</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Véronique GILLON, Responsable URC</last_name>
      <phone>33 (0)3 83 59 85 74</phone>
      <email>v.gillon@nancy-unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Maria RIOS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ivan KRAKOWSKI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nadia AMELLAL, MD</last_name>
      <phone>33 (0)1 42 11 66 70</phone>
      <email>nadia.amellal@igr.fr</email>
    </contact>
    <contact_backup>
      <last_name>Rosa DA SILVA, CRA Manager</last_name>
      <phone>33 (0)1 42 11 40 27</phone>
      <email>rosa.dasilva@igr.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Olivier MIR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Axel LE CESNE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien DOMONT, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>France</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 17, 2014</lastchanged_date>
  <firstreceived_date>July 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sarcoma</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Regorafenib</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
